Tryg (CPSE:TRYG) Posted Stronger Q3 Earnings, Is The Stock Still Undervalued?

How Tryg’s latest earnings set the context

Tryg (CPSE:TRYG) has just reported third quarter results, with net income of DKK 1,625 million and basic earnings per share of DKK 2.68, while year to date earnings remain lower than in the prior period.

Tryg’s share price has moved to DKK153.1, with a 7 day share price return of 3.1% but a year to date share price return that is down 7.3%, while the 1 year total shareholder return of 1.5% and 3 year total shareholder return of 31.9% point to stronger longer run performance than the recent trend suggests.

Scan how Tryg compares with other insurers by checking a curated set of 233 resilient stocks with low risk scores that have weathered recent market swings with relatively resilient profiles.

Tryg shares have climbed over the past week yet remain down for the year, which puts a simple question in front of you: Does it make sense to step in now, or wait for a cheaper entry based on valuation?

Most Popular Narrative: 8% Undervalued

Tryg’s most followed valuation narrative puts fair value at DKK165.67 versus the latest close at DKK153.1, which frames the stock as modestly undervalued and places execution on costs, claims and capital at center stage.

The company continues to work toward its insurance service result target of DKK 8.0b to DKK 8.4b and a combined ratio around 81% for 2027, and reiterated in 2026 that these goals are unchanged, which ties its operational programmes directly to future revenue and earnings potential.

See why 23 investors see Tryg as 8% undervalued.

Result: Fair Value of DKK165.67 (UNDERVALUED)

Still, the Tryg story can change quickly if inflation keeps pressuring claims costs, or if regulators curb indexation and limit how much pricing power offsets that.

Find out about the key risks to this Tryg narrative.

Another View: What Tryg’s P/E Is Telling You

There is a catch. While the SWS fair value of DKK165.67 frames Tryg as undervalued, the P/E ratio of 19.6x looks expensive next to the European insurance group on 12.5x and a peer average of 15.7x, even if it still sits below a fair ratio of 22.6x. Is that premium a cushion, or a valuation risk in your eyes?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals on Tryg so far. Do not wait for someone else to decide what that means for you. Evaluate the balance of risks and rewards yourself, starting with the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Tryg?

If Tryg has sharpened your thinking on valuation and risk, do not stop there. Broaden your watchlist with a few focused stock idea sets that match your goals.

• Target resilient balance sheets by scanning a list of solid balance sheet and fundamentals (203 results) that can help you stress test your portfolio for tougher conditions.
• Hunt for potential mispricing and compare them to Tryg by checking a 191 high quality undervalued stocks that filters for quality first, not hype.
• Build a steadier income stream by reviewing a 214 dividend fortresses that highlights higher yield opportunities with fundamentals on the table.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com